NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies
- PMID: 12428105
NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies
Abstract
Antiphospholipid antibodies (aPLA) are associated with thrombophilia and recurrent pregnancy loss. They bind directly to anionic phospholipids or via phospholipid-binding proteins such as beta(2)-glycoprotein 1 (beta(2)GP1). The underlying mechanisms by which aPLA induce a thrombophilic phenotype are not well understood. The present work was done to determine whether antibodies to beta(2)GP1 activate endothelial cells (EC) and whether NFkappaB is involved in this activation. Incubation of EC with these antibodies resulted in a redistribution of NFkappaB from the cytoplasm to the nucleus after a delay of several hours. This was accompanied by an increased expression of tissue factor and of the leukocyte adhesion molecules ICAM-1, VCAM-1 and E-selectin. Inhibition of the nuclear translocation of NFkappaB abolished the response to these antibodies. In comparison to anti-beta(2)GP1 antibodies, incubation of EC with TNF resulted in a more rapid (within 30 minutes) redistribution of NFkappaB and a more pronounced expression of tissue factor and of the leukocyte adhesion molecules. The slower response to the antibodies as compared to TNF suggests that the NFkappaB response to anti-beta(2)GP1 antibodies is indirect. Taken together our results imply that NFkappaB is an essential intermediate in the activation of EC by anti-beta(2)GP1 antibodies.
Similar articles
-
Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies.Blood. 2003 May 1;101(9):3495-500. doi: 10.1182/blood-2002-08-2349. Epub 2003 Jan 16. Blood. 2003. PMID: 12531807
-
Endothelium as a target for antiphospholipid antibodies.Immunobiology. 2003;207(1):29-36. doi: 10.1078/0171-2985-00211. Immunobiology. 2003. PMID: 12638900 Review.
-
ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism.Vascul Pharmacol. 2011 Nov-Dec;55(5-6):135-42. doi: 10.1016/j.vph.2011.07.003. Epub 2011 Jul 12. Vascul Pharmacol. 2011. PMID: 21777697
-
Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies.J Immunol. 1998 Jun 1;160(11):5572-8. J Immunol. 1998. PMID: 9605162
-
Annexin A2: better left alone.Blood. 2005 Mar 1;105(5):1845-6. doi: 10.1182/blood-2004-12-4786. Blood. 2005. PMID: 15747402 Review.
Cited by
-
Exosome-Contained APOH Associated With Antiphospholipid Syndrome.Front Immunol. 2021 May 4;12:604222. doi: 10.3389/fimmu.2021.604222. eCollection 2021. Front Immunol. 2021. PMID: 34040601 Free PMC article.
-
Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.Ann Rheum Dis. 2007 Aug;66(8):1000-7. doi: 10.1136/ard.2006.063909. Epub 2007 Jan 12. Ann Rheum Dis. 2007. PMID: 17223652 Free PMC article.
-
Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome.Front Immunol. 2024 Jul 9;15:1361519. doi: 10.3389/fimmu.2024.1361519. eCollection 2024. Front Immunol. 2024. PMID: 39044818 Free PMC article. Review.
-
Antiphospholipid syndrome: multiple mechanisms.Clin Exp Immunol. 2004 Jun;136(3):393-401. doi: 10.1111/j.1365-2249.2004.02497.x. Clin Exp Immunol. 2004. PMID: 15147339 Free PMC article. Review. No abstract available.
-
Update on Antiphospholipid Syndrome: Ten Topics in 2017.Curr Rheumatol Rep. 2018 Mar 15;20(3):15. doi: 10.1007/s11926-018-0718-4. Curr Rheumatol Rep. 2018. PMID: 29541874 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous